TXNDC17

Across TCGA pan-cancer cohorts, TXNDC17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TXNDC17 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TXNDC17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TXNDC17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where TXNDC17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.134	1.000	.008	6	view →
UCEC	DFS	Median	II,III,IV	0.870	0.546	.047	4	view →
LUAD	OS	Quartile	III,IV	0.821	0.366	.019	2	view →
LSCC	DFS	Median	II,III,IV	0.975	0.865	.041	1	view →
GBM	OS	Tertile	All	0.564	0.884	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TXNDC17–HNSC (OS)

Open the HNSC breakdown →